|
 Agilent Technologies, a global leader in life sciences, diagnostics, and applied chemical markets opened its new Biopharma Experience Center in Hyderabad, Telangana. The facility marks a significant investment in India’s rapidly growing life sciences ecosystem and reflects Agilent’s long-term commitment to advancing biopharmaceutical innovation both locally and globally.
The centre was inaugurated by Telangana Minister for Information Technology, Electronics, Communications, and Industries, Duddila Sridhar Babu, in the presence of Padraig McDonnell, president, and CEO, Agilent along with senior leaders from India’s pharmaceutical and biopharma sectors.
The new Agilent Biopharma Experience Center in Hyderabad presents a major opportunity to accelerate the city’s leadership in life sciences and healthcare innovation. Designed to support the full drug development journey, the centre brings together advanced lab technologies, expert training, and regulatory-ready workflows to help researchers, scientists, and companies develop high-quality, life-saving medicines faster and more efficiently. It offers end-to-end solutions across key modalities such as chromatography, mass spectrometry, cell analysis, and lab informatics, allowing companies to simulate real lab environments, test for quality and compliance, and co-create market-ready solutions tailored to both Indian and global needs.
“India is a strategic growth market for Agilent, and Hyderabad is at the forefront of biopharma innovation. “Our future will be defined by continued innovation and a relentless focus on our customers. This new centre reflects our commitment to delivering integrated solutions that help bring life-changing therapies to market faster and more efficiently. It also reinforces our support for the ‘Make-in-India’ initiative by empowering local innovation, nurturing talent, and enabling scalable, affordable, and sustainable solutions,” said Padraig McDonnell, CEO, Agilent Technologies.
Minister Duddila Sridhar Babu, said, “Hyderabad has emerged as a complete healthcare and life sciences ecosystem—from drug discovery and clinical trials to world-class hospitals and affordable, high-quality patient care. We are proud to host eight of the top ten global pharma companies, five of India’s leading healthcare chains, and over 230 US FDA-approved manufacturing facilities. Contributing nearly one-third of India’s pharmaceutical production and 40% of bulk drug exports, Telangana is making a strong impact both nationally and globally. With a strong talent base and a clear focus on innovation, we are building a future-ready healthcare system. The launch of the Agilent Biopharma Experience Center is a significant milestone in strengthening Telangana’s position as a global leader in life sciences, and a valuable addition to our expanding innovation-driven ecosystem.”
This capital investment is part of Agilent’s broader three-to-five-year India growth strategy, which includes expanding its footprint, deepening customer partnerships, and positioning India as a strategic hub in Agilent’s global innovation and profitability roadmap. The India Solution Center in Manesar, launched earlier this year, further reflects this ongoing commitment contributing to Agilent’s efforts to enhance its presence and capabilities in one of its fastest-growing, high-priority markets globally. Agilent is already working closely with many of India’s leading biopharma companies. With this centre, we aim to strengthen those relationships and co-create solutions that meet the evolving needs of the Indian and global markets,” added McDonnell.
|